People and Business News – 5/23
The latest people and business news from the past month, all in one place.
People News
Parexel announced the addition of Dr. Scott Smith as SVP, global therapeutic area head of hematology. Prior to joining Parexel, he held several positions at Loyola Medicine's Cardinal Bernardin Cancer Center.
The Almac Group announced the appointment of Ramees Raja as global energy manager. Previously, he spent the previous two years as energy manager for Muntons Pic.
Oracle announced that Seema Verma has been named senior vice president and general manager, life sciences. Most recently, she served as a senior advisor to private equity firms Cressy & Co. and TPG.
Science 37 revealed that they have hired Erica Prowisor as SVP, patient and provider networks. Before this, she spent time as the global head of recruitment and retention for IQUVIA.
American Clinical Research Services appointed Dustin Owen as the new CEO. Previously, Mr. Owen worked at Thermo Fisher Scientific/PPD, where he was SVP and general manager of accelerated enrollment solutions.
Velocity Clinical Research announced the hiring of three executives. Nick Campbell joins as chief commercial officer, Nick Spittal as chief operating officer, and Steph Anderson has been promoted to chief of staff.
ArisGlobal announced the appointment of Julie Springer as the company’s first chief marketing officer. Julie joins ArisGlobal following tenures as CMO at Fast Radius as well as at TransUnion, where she helped lead the company on a significant transformation journey and highly successful IPO.
uMotiff named SAFIRA Clinical Research Co-founder and clinical trial technology innovator Willie Muehlhausen Scientific Advisor, offering 20 years of experience.
Business News
Elligo Health Research opened a new clinical research center in Austin, TX. According to the company, this new center is three times larger than the original location at their headquarters.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
